Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.54 |
| ▸ | CES2 | O00748 | 6/20 | 0.54 |
| ▸ | CES1 | P23141 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Heptane SCHEMBL3918420 | 1.00 | FAAH (0.54) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL3673750 | 0.98 | FAAH (0.52) | FAAHCES2CES1MEN1CYP1A2 | |
| Heptane SCHEMBL7647372 | 0.96 | FAAH (0.50) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28128351 | 0.95 | FAAH (0.50) | FAAHCES2CES1MEN1CYP1A2 | |
| Trifluoroacetic Acid SCHEMBL28015086 | 0.93 | FAAH (0.48) | FAAHCES2CES1MEN1CYP1A2 | |
| Octane SCHEMBL1696265 | 0.91 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 | |
| Hexadecane SCHEMBL4765353 | 0.91 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 | |
| Undecane SCHEMBL3628539 | 0.91 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 | |
| Heptane SCHEMBL3935940 | 0.91 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 | |
| Nonane SCHEMBL4255344 | 0.91 | FAAH (0.62) | FAAHCES2CES1MEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6916841-B2 | Inhibitors of phospholipase enzymes | GENETICS INSTITUTE, LLC (US) | 2005-07-12 | — | — | US | disclosed |
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | AMERICAN HOME PRODUCTS CORPORATION | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153751-A1 | Inhibitors of phospholipase enzymes | PLA2G4C, PLA2G4B, PLA2G4A | FAAH 218/4885CES2 298/4885CES1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.